FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072748875> ?p ?o ?g. }

• W2072748875 endingPage "36" @default.
• W2072748875 startingPage "36" @default.
• W2072748875 abstract "Background: (AL) Amyloidosis is a rare and potentially fatal disease that involves deposition of light chain protein by a clonal plasma cell population. Treatment with high dose melphalan and autologous stem cell transplant (ASCT) can improve survival and reverse organ damage, but this treatment is associated with toxicity and mortality. We reviewed the outcome of patients with amyloidosis, who received hematopoietic stem cell transplant (HSCT) at our institution. Patients and Methods: The retrospective study analyzed 32 patients with AL Amyloidosis who underwent transplant between 1997–2006. There were 17 men and 15 women, with a medium age of 53 years (range 35–73 years). All patients had diagnostic criteria for multiple myeloma (MM) and had biopsy confirmed amyloidosis of at least one organ site. Six patients had at least 1 organ involved with AL amyloidosis (3 bone marrows, 2 subcutaneous and 1 kidney), 20 patients had 2 organs involved, while 6 patients had 3 or more organs affected. Twenty-eight patients underwent autologous transplant, while 4 had an allogeneic transplants (2 syngeneic and 2 siblings). The preparative regimens received in 28 patients were high dose melphalan (26 autologous and 2 syngeneic), 2 patients received Busulfan and Melphalan, 2 allogeneic transplant Fludarabine and Melphalan. Results: The median Charlson Comorbidities Index (CCI) was 3 (range 0–8). The median number of CD34+ cells infused was 4.85 × 106 cells/kg (range 1.43–7.82 cells/kg). The median time to neutrophil and platelet engraftment were 11 (range 2–21 days) and 14 days (range 2–41), respectively. 56% of patients developed moderate to severe gastrointestinal effects. Four patients underwent allogeneic transplant and 1 had acute and chronic graft vs host disease (GVHD). Twenty-one patients (65%) achieved a partial hematological remission (PR), and 5 patients (15%) achieved complete hematological remission (CR), with a total response hematological rate of 80%. The 100 day NRM was 3.2%. The median overall survival was (OS) 41 months (range 1–108), 7 patients died (4 relapsed and 3 infections) all 7 patients had CCI greater or equal to 4. Conclusion: Selected patients with MM and amyloidosis can benefit from high dose therapy with stem cell support including allogeneic transplantation. The high mortality seen in patients with CCI >4 suggests that this index could be useful in selecting patients for high dose chemotherapy." @default.
• W2072748875 created "2016-06-24" @default.
• W2072748875 creator A5001231771 @default.
• W2072748875 creator A5013081371 @default.
• W2072748875 creator A5015342719 @default.
• W2072748875 creator A5026910190 @default.
• W2072748875 creator A5027513506 @default.
• W2072748875 creator A5034264716 @default.
• W2072748875 creator A5048913229 @default.
• W2072748875 creator A5055929208 @default.
• W2072748875 creator A5070096873 @default.
• W2072748875 date "2008-02-01" @default.
• W2072748875 modified "2023-09-27" @default.
• W2072748875 title "91: Myeloma with AL Amyloidosis: 10 Years Experience with Stem Cell Transplant" @default.
• W2072748875 doi "https://doi.org/10.1016/j.bbmt.2007.12.100" @default.
• W2072748875 hasPublicationYear "2008" @default.
• W2072748875 type Work @default.
• W2072748875 sameAs 2072748875 @default.
• W2072748875 citedByCount "0" @default.
• W2072748875 crossrefType "journal-article" @default.
• W2072748875 hasAuthorship W2072748875A5001231771 @default.
• W2072748875 hasAuthorship W2072748875A5013081371 @default.
• W2072748875 hasAuthorship W2072748875A5015342719 @default.
• W2072748875 hasAuthorship W2072748875A5026910190 @default.
• W2072748875 hasAuthorship W2072748875A5027513506 @default.
• W2072748875 hasAuthorship W2072748875A5034264716 @default.
• W2072748875 hasAuthorship W2072748875A5048913229 @default.
• W2072748875 hasAuthorship W2072748875A5055929208 @default.
• W2072748875 hasAuthorship W2072748875A5070096873 @default.
• W2072748875 hasBestOaLocation W20727488751 @default.
• W2072748875 hasConcept C126322002 @default.
• W2072748875 hasConcept C141071460 @default.
• W2072748875 hasConcept C159654299 @default.
• W2072748875 hasConcept C203014093 @default.
• W2072748875 hasConcept C2776364478 @default.
• W2072748875 hasConcept C2777408962 @default.
• W2072748875 hasConcept C2778684742 @default.
• W2072748875 hasConcept C2779551797 @default.
• W2072748875 hasConcept C2779951007 @default.
• W2072748875 hasConcept C2780611847 @default.
• W2072748875 hasConcept C2911091166 @default.
• W2072748875 hasConcept C36394416 @default.
• W2072748875 hasConcept C71924100 @default.
• W2072748875 hasConcept C90924648 @default.
• W2072748875 hasConceptScore W2072748875C126322002 @default.
• W2072748875 hasConceptScore W2072748875C141071460 @default.
• W2072748875 hasConceptScore W2072748875C159654299 @default.
• W2072748875 hasConceptScore W2072748875C203014093 @default.
• W2072748875 hasConceptScore W2072748875C2776364478 @default.
• W2072748875 hasConceptScore W2072748875C2777408962 @default.
• W2072748875 hasConceptScore W2072748875C2778684742 @default.
• W2072748875 hasConceptScore W2072748875C2779551797 @default.
• W2072748875 hasConceptScore W2072748875C2779951007 @default.
• W2072748875 hasConceptScore W2072748875C2780611847 @default.
• W2072748875 hasConceptScore W2072748875C2911091166 @default.
• W2072748875 hasConceptScore W2072748875C36394416 @default.
• W2072748875 hasConceptScore W2072748875C71924100 @default.
• W2072748875 hasConceptScore W2072748875C90924648 @default.
• W2072748875 hasIssue "2" @default.
• W2072748875 hasLocation W20727488751 @default.
• W2072748875 hasOpenAccess W2072748875 @default.
• W2072748875 hasPrimaryLocation W20727488751 @default.
• W2072748875 hasRelatedWork W2003715807 @default.
• W2072748875 hasRelatedWork W2012879531 @default.
• W2072748875 hasRelatedWork W2034080653 @default.
• W2072748875 hasRelatedWork W2049733656 @default.
• W2072748875 hasRelatedWork W2081068834 @default.
• W2072748875 hasRelatedWork W2103595935 @default.
• W2072748875 hasRelatedWork W2404726030 @default.
• W2072748875 hasRelatedWork W2409657474 @default.
• W2072748875 hasRelatedWork W2609795796 @default.
• W2072748875 hasRelatedWork W2992485704 @default.
• W2072748875 hasVolume "14" @default.
• W2072748875 isParatext "false" @default.
• W2072748875 isRetracted "false" @default.
• W2072748875 magId "2072748875" @default.
• W2072748875 workType "article" @default.